Rockefeller Capital Management
SWTX

Rockefeller Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Rockefeller Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,478
Closed -$108K – 3601
2021
Q1 		$108K Buy
+1,478
New +$116K ﹤0.01% 1563

Other funds holding SWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Rockefeller Capital Management's SWTX Position: Q2 2021 in Review

Rockefeller Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2021, closing a stake of 1,478 shares — an estimated $108K sold.

Rockefeller Capital Management first reported a position in SWTX in Q1 2021 and held it in 1 quarter. The position peaked at $108K in Q1 2021. 135 funds tracked by Wall St. Rank hold SWTX as of Q2 2021.

  • Rockefeller Capital Management reported no remaining SpringWorks Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Rockefeller Capital Management sold 1,478 SpringWorks Therapeutics shares in Q2 2021, an estimated $108K.
  • Rockefeller Capital Management first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 1 quarter.
  • Rockefeller Capital Management's SpringWorks Therapeutics position peaked at $108K in Q1 2021.
  • 135 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2021.

Based on Rockefeller Capital Management's 13F filing for Q2 2021, filed 10 Aug 2021.